Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

APPRAISE-1 (10mg od), 2009 - apixaban vs placebo

SEPIA-ACS1 TIMI 42, 2009 - otamixaban vs unfractioned heparin

PLATO, 2009 - ticagrelor + aspirin vs clopidogrel + aspirin

ATLAS ACS-TIMI 46, 2009 - rivaroxaban vs placebo

APPRAISE-1 (2.5 mg bid), 2009 - apixaban vs placebo

DISPERSE-2 (90mg), 2007 - ticagrelor + aspirin vs clopidogrel + aspirin

INTERACT, 2006 - enoxaparin vs UFH (on top of aspirin)

OASIS 5, 2006 - fondaparinux vs enoxaparin

PROTECT-TIMI 30, 2006 - Bivalirudin vs eptifibatide + heparin

SYNERGY, 2005 - enoxaparin vs UFH (on top of aspirin)

EVET, 2005 - enoxaparin vs tinzaparin

LoWASA, 2004 - warfarin vs control (on top of aspirin)

PENTUA, 2004 - fondaparinux vs enoxaparin

Zibaeenezhad, 2004 - warfarin vs control (on top of aspirin)

APRICOT-2, 2002 - warfarin vs control (on top of aspirin)

ASPECT-2 (coumadin+asp vs asp), 2002 - coumadin vs control (on top of aspirin)

WARIS, 2002 - warfarin vs control (on top of aspirin)

ASPECT-2 (coumadin vs aspirin), 2002 - coumadin vs aspirin

CHAMP, 2002 - warfarin vs control (on top of aspirin)

OASIS-2 Warfarin Substudy, 2001 - warfarin vs control (on top of aspirin)

CURE, 2001 - clopidogrel + aspirin vs aspirin

Huyhn, 2001 - warfarin vs placebo (on top of aspirin)

TIM, 2000 - triflusal vs aspirine

HIT-4, 1999 - Hirudin vs heparin

Klootwijk, 1999 - Efegatran vs heparin



See also:

  • All acute coronary syndrome clinical trials
  • All clinical trials of antithrombotics
  • All clinical trials of aspirin
    		•  

    ATACS-pilot study, 1990

    Treatments

    Studied treatment Aspirin 80mg/d (Heparin + Warfarin)
    Control treatment full-dose heparin followed by warfarin

    Patients

    Patients acute coronary syndromes

    Method and design

    Randomized effectives 37 / 24 (studied vs. control)
    Follow-up duration 3m


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    Non fatal MI

    0 / 37
         3 / 24
         classic 0,05 [0,00;2,82]

    Vascular events

    0 / 37
         4 / 24
         classic 0,04 [0,00;2,08]

    Major bleeding

    0 / 37
         0 / 24
         classic 0,65 [0,00;161,90]

    Vascular death

    0 / 37
         1 / 24
         classic 0,13 [0,00;9,22]

    Non vascular death

    0 / 37
         0 / 24
         classic 0,65 [0,00;161,90]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    Non fatal MI 0 / 37 (1,4%) 3 / 24 (12,5%) 0,11 [0,01;2,06]    
    Vascular death 0 / 37 (1,4%) 1 / 24 (4,2%) 0,32 [0,01;9,30]    
    Non vascular death 0 / 37 (1,4%) 0 / 24 (2,1%) 0,65 [0,01;31,61]    
    Vascular events 0 / 37 (1,4%) 4 / 24 (16,7%) 0,08 [0,00;1,47]    
    Major bleeding 0 / 37 (1,4%) 0 / 24 (2,1%) 0,65 [0,01;31,61]    
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 0:

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.


    Reference(s)

    Trials register # NA
    • Cohen M, Adams PC, Hawkins L, Bach M, Fuster V. Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group).. Am J Cardiol 1990 Dec 1;66:1287-92
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend